2 Information about rucaparib

Information about rucaparib

Marketing authorisation indication

Rucaparib (Rubraca, Clovis Oncology) is indicated as 'monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.'

Dosage in the marketing authorisation

Rucaparib is taken orally as tablets. The recommended dosage is 600 mg (2 × 300-mg tablets) twice daily, with or without food (1,200 mg total daily dose).

Interruption of treatment or dose reduction can be considered for adverse event management (600 mg to 500 mg [2 × 250-mg tablets] to 400 mg [2 × 200-mg tablets] to 300 mg [1 × 300-mg tablet]).

Patients should start maintenance treatment no later than 8 weeks after completion of their final dose of the platinum-containing regimen.


The list price for rucaparib taken from the company submission is £3,562.00 per 60‑tablet pack of 300-mg, 250-mg or 200-mg tablets.

The company estimates that the average cost of a course of treatment until discontinuation is £110,897 (estimated from the deterministic base-case economic analysis using the list price).

The company has a commercial arrangement. This makes rucaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)